Compare Asana Inc. (ASAN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Asana Inc. vs Merck & Co., Inc. — how do they compare? Asana Inc. trades at $7.36 (market cap $1.69B), while Merck & Co., Inc. trades at $123.84 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 180.5× Asana Inc.'s market cap, and Merck & Co., Inc. pays a 2.75% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | MRK | |
|---|---|---|
Market Cap | $1.69B | $305.12B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.35 | $129.52 |
52-Week Low | $5.46 | $77.60 |
Enterprise Value | $1.51B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $7.33, down 0.54% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $378M in 2022 to $724M in 2025, though net losses persist. Recent Q1 2027 earnings beat expectations at $0.10 per share, and strategic acquisitions like StackAI enhance AI capabilities. Analyst consensus is mixed with 42% buy ratings and a $9.86 price target, representing 35% upside from current levels.
The outlook balances growth potential against profitability challenges. Positive catalysts include FedRAMP authorization for government contracts and AI innovation, but risks stem from intense competition with Microsoft and decelerating revenue growth. Cash flow turned positive in 2025, yet negative margins and high valuation multiples require careful monitoring for sustained improvement.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income reached $18.25B, reflecting a robust 28.07% profit margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for MRK remains positive driven by earnings momentum and strategic acquisitions, though risks include rising debt levels and competitive pressures. Wall Street sentiment is bullish with 68% buy ratings, but investors should monitor execution of the Terns integration and patent expirations. The stock offers potential upside to the price target with solid fundamentals supporting long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
